Immix Biopharma reports 100% ORR for CAR-T NXC-201 in r/r AL amyloidosis

Immix Biopharma announced new clinical data from its Phase 1b/2a NEXICART-1 study of novel, autologous, BCMA-targeted chimeric antigen receptor T cell therapy, NXC-201, in patients with relapsed/refractory AL Amyloidosis at an oral presentation by study investigator Moshe E. Gatt, MD at the 65th American Society of Hematology Meeting being held in San Diego, CA. The updated results include follow-up and clinical data from one new patient. All patients were relapsed/refractory to standard-of-care Dara-CyBorD and had experienced a median of 6 prior lines of therapy that failed to stop worsening of disease prior to receiving NXC-201. “There is a rising prevalence of relapsed/refractory AL Amyloidosis patients who have no approved options for treatment,” said Polina Stepensky, M.D., Director of the Hadassah Medical Organization’s Department of Bone Marrow Transplantation and Immunotherapy for Adults and Children, and principal study investigator. “We continue to be encouraged by NXC-201’s 100% overall response rate, including in this 10th relapsed/refractory AL amyloidosis patient.” Safety and efficacy data: Overall response rate of 100%; Complete response + very good partial response rate of 90%;Complete response rate of 70%; Organ response rate of 60%; Best responder had a duration of response of 23.7 months as of December 10, 2023, with response ongoing.